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Introduction
Breast cancer remains a major cause of cancer death in
women in the developed world. Novel therapeutic modali-
ties are needed for those patients in whom chemotherapy,
hormonal treatment and external radiation therapy are inef-
fective. 2-Deoxy-2-[18F]fluoro-D-glucose (18F-FDG) is
widely used in positron emission tomography (PET) for the
evaluation of patients with tumors [1,2]. It was shown by
Warburg in 1930 that glucose is actively utilized by tumor
cells [3]. In recent years the use of 18F-FDG-PET has
become well established in the diagnosis of breast
cancer, because many breast cancers demonstrate high
avidity for 18F-FDG [4], which is an analogue of glucose in
which the hydroxy group in the 2 position has been
replaced with a fluorine atom. 18F-FDG is taken up by the
cells and phosphorylated by hexokinase to 18F-FDG-6-
18F-FDG = 2-deoxy-2-[18F]fluoro-D-glucose; H&E = haematoxylin and eosin; MMTV = mouse mammary tumor virus; PET = positron emission
tomography; PyMT = polyoma middle T antigen; SUV = standardized uptake value; TLR = tumor to liver ratio.
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Abstract
Background: Novel approaches are needed for breast cancer
patients in whom standard therapy is not effective. 2-Deoxy-2-
[18F]fluoro-D-glucose (18F-FDG) was evaluated as a potential
radiomolecular therapy agent in breast cancer animal models
and, retrospectively, in patients with metastatic breast cancer.
Methods: Polyoma middle T antigen (PyMT) and mouse
mammary tumor virus-NeuT transgenic mice with tumors
0.5–1cm in diameter were imaged with 18F-FDG, and tumor to
liver ratios (TLRs) were calculated. The radiotoxicity of 18F-FDG
administration was determined in healthy mice. PyMT mice with
small (0.15–0.17cm) and large (more than 1cm) tumors were
treated with 2–4mCi of 18F-FDG, and control C3H/B6 mice
with 3mCi of 18F-FDG. At 10 days after treatment the tumors
and control mammary glands were analyzed for the presence of
apoptotic and necrotic cells. Five patients with breast cancer
and metastatic disease were evaluated and standardized
uptake values (SUVs) in tumors, maximum tolerated dose, and
the doses to the tumor were calculated.
Results: Doses up to 5mCi proved to be non-radiotoxic to
normal organs. The 18F-FDG uptake in mouse tumors showed
an average TLR of 1.6. The treatment of mice resulted in
apoptotic cell death in the small tumors. Cell death through
the necrotic pathway was seen in large tumors, and was
accompanied by tumor fragmentation and infiltration with
leukocytes. Normal mammary tissues were not damaged. A
human  18F-FDG dose delivering 200 rad to the red marrow
(less than 5% damage) was calculated to be 4.76Ci for a
70kg woman, and the dose to the tumors was calculated to
be 220, 1100 and 2200 rad for SUVs of 1, 5 and 10,
respectively.
Conclusion: We have shown that positrons delivered by
18F-FDG to mammary tumors have a tumoricidal effect on
cancer cells. The study of breast cancer patients suggests that
the tumor and normal organ dosimetry of 18F-FDG makes it
suitable for therapy of this malignancy.
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phosphate. Because 18F-FDG is not a substrate for glycol-
ysis and does not undergo further metabolism, it remains
trapped in the cell [5].
18F emits positrons with an average energy of 0.250MeV
and abundance of 96%. Positrons lose their kinetic energy
in the tissue in the same manner as electrons, thereby
damaging tissue. This is followed by annihilation, which
results in the emission of two photons with an energy of
511keV in opposite directions. Although the potential of
electrons to kill cancer cells through the loss of their
kinetic energy has been made use of in radionuclide
cancer treatment for more than 50 years (since the intro-
duction of therapy of thyroid cancer with 131I [6]), the ther-
apeutic potential of positrons has remained unexplored.
Theoretically, positrons should kill cancer cells during the
loss of kinetic energy in the same manner as electrons.
Here we evaluate, for the first time to our knowledge, the
potential of 18F-FDG as a positron-emitting agent for the
radiomolecular therapy of breast cancer in breast cancer
animal models and, retrospectively, in patients with
metastatic breast cancer.
Materials and methods
Animals
All procedures involving mice were conducted in accor-
dance with the National Institutes of Health regulations con-
cerning the use and care of experimental animals. The study
of mice was approved by the Albert Einstein College of
Medicine Animal Use Committee. Transgenic mice express-
ing the polyoma middle T antigen (PyMT) in the mammary
epithelium under the control of mouse mammary tumor virus
(MMTV) long terminal repeat were provided by Dr WJ
Muller (McMaster University, Ontario, Canada) and then
bred in our institution. At the age of 10 weeks these mice
have multiple mammary tumors 0.15–0.17cm in diameter.
In mice older than 18 weeks the tumors are more than 1cm
in diameter. MMTV-NeuT mice [7], which carry erbB-2
(Neu), one of the better known human breast cancer onco-
genes, were purchased from Jackson Laboratories. MMTV-
NeuT mice were obtained as retired breeders and some of
them developed mammary tumors at the age of 5 months,
whereas others remained-tumor free until 6–7 months of
age. C3H/B6 female mice lacking the PyMT transgene
were used as healthy controls in therapy experiments.
Imaging of mice with 18F-FDG
PyMT mice older than 18 weeks, with tumors more than
1cm in diameter, MMTV-NeuT tumor-bearing mice
(0.5–1cm in diameter) and tumor-free MMTV-NeuT mice
were fasted for 4 hours before the injection of radiotracer.
Three animals were used in each group. They were anes-
thetized with a mixture of 125mg/kg ketamine and
10mg/kg xylazine. An injection of 0.5–2.0mCi 18F-FDG
was administered intraperitoneally (i.p.). The mice rested
while anesthetized for an uptake period of 1 hour. A scan
was performed on a dedicated PET scanner CPET
(Philips). Scans (6 min emission and 45 s transmission)
were obtained. The data were acquired with a zoom of 2
and a slice thickness of 2mm. Images were reconstructed
with an iterative reconstruction algorithm and corrected for
attenuation. To reduce volume averaging, a small round
region of interest 12 pixels in size was drawn in the center
of the tumor and in the center of normal liver. The diameter
of the region was 7mm. The tumor to liver ratios (TLRs)
were calculated by the formula TLR=counts per pixel in
tumor divided by counts per pixel in liver.
Radiotoxicity studies of 18F-FDG in healthy mice
After a 4-hour fast, 2 groups of BALB/c mice were treated
i.p. with the following doses of 18F-FDG: group 1 (three
mice), 2.5mCi; group 2 (three mice), 5mCi; group 3
(three mice), left untreated for control. The mice were
monitored for changes in behavior and body weight for
1 month, after which they were killed; their heart, brain,
liver, kidneys, bladder, and bone marrow were removed,
fixed in buffered formalin, sectioned, stained with hema-
toxylin and eosin (H&E), and analyzed histologically.
Treatment of PyMT mice with 18F-FDG
After a 4-hour fast, three groups of mice were treated i.p.
with the following doses of 18F-FDG: group 1 (five
10-week-old mice), 2–4mCi; group 2 (three 22-week-old
mice), 2mCi; group 3 (two C3H/B6 mice), 3mCi to assess
radiation damage to healthy breast tissue. Three 10-week-
old and two 22-week-old PyMT mice served as untreated
controls. At 10 days after treatment, mice were killed. In
younger mice, the right abdominal mammary glands were
removed for whole mount preparation as described [8],
then fixed in buffered formalin and sectioned. In older mice,
the tumors were removed and processed as above. Some
sections were stained with H&E; others were analyzed for
the presence of apoptotic and necrotic cells.
Apoptosis and necrosis detection
The detection of apoptotic and necrotic cells in the tumors
was performed with an Apoptag Plus® apoptosis detec-
tion kit (Serologicals) in accordance with the manufactur-
er’s instructions. In brief, 3′-OH termini of DNA fragments,
which are the hallmark of apoptosis, were labeled with
digoxigenin-modified nucleotides by terminal deoxynu-
cleotidyl transferase. This enzyme selectively detects
apoptotic over necrotic cells. The labeled DNA was
detected with an anti-digoxigenin antibody, and detection
was performed with a chromagen: apoptotic cells were
stained brown, and areas of necrosis were stained yellow.
18F-FDG-PET in breast cancer patients with metastatic
disease
Approval was obtained from the Albert Einstein College
of Medicine Cancer Center Protocol Review CommitteeR201
and the Montefiore Medical Center Institutional Review
Board. Retrospectively, five consecutive patients with
breast cancer and metastatic disease shown on
18F-FDG-PET scanning were evaluated. After more than
4 hours of fasting, the patients were administered
3.5mCi of 18F-FDG, and rested during an uptake period
of 45 min. The patients then underwent a whole-body
scan on the CPET scanner. The scanning protocol con-
sisted of 6 min of emission and two rotations of a 137Cs
source for transmission per bed position, and approxi-
mately six bed positions. Images were corrected for atten-
uation and reconstructed with the iterative method. To
reduce volume averaging, a small round region of interest
12 pixels in size was drawn in the center of the tumor and
in the center of normal liver. The diameter of the region
was 14mm. Standardized uptake values (SUVs) were cal-
culated for all regions of interest by the formula
SUV=(activity in tissue [mCi/g]) divided by (injected
activity [mCi]/body weight [g]).
TLRs were calculated by the formula TLR=SUV of tumor
divided by SUV of liver.
The dose-limiting organ for therapy with 18F-FDG is the
bone marrow. The activity of 18F-FDG that will deliver
doses of 200 rad to the red marrow (less than 5%
damage in 5 years) [9] and also 300 rad were calculated
using the Medical Internal Radionuclide Dosimetry formal-
ism. A dose of 300 rad was considered because it causes
acceptable and manageable hematologic toxicity in
selected patients [9]. The subsequent doses delivered to
18F-FDG-avid tumors were calculated.
Results
Uptake of 18F-FDG in mammary tumors of PyMT and
MMTV-neuT mice
Coronal PET images of PyMT and MMTV-neuT mice
injected with 18F-FDG are presented in Figure 1. Slices
(2mm thickness) with the highest activity in the tumor were
chosen. There was significant uptake of 18F-FDG by the
tumors in PyMT (Fig.1a,b) and MMTV-neuT mice (Fig.1c).
The tumor uptake was uniform. TLRs were (mean ± SD)
1.6±0.4 and 1.6±0.1 in MMTV-neuT and PyMT mice,
respectively. No abnormal uptake was seen in a tumor-free
mouse (Fig.1d). As 18F-FDG is normally excreted in the
urine, bladder activity was visible in all mice. The avidity of
tumors for 18F-FDG provided an impetus for investigation
of the therapeutic effect of 18F-FDG on mammary tumors in
mice.
Lack of radiotoxicity of 18F-FDG in normal mice
Treatment of healthy mice with doses of up to 5mCi
18F-FDG caused no damage in major organs (as deter-
mined by histological examination) including bone marrow,
which is a dose-limiting organ in patients (results not
shown).
Toleration of treatment of PyMT mice with 18F-FDG
PyMT mice treated with 2–4mCi 18F-FDG were observed
for 10 days for obvious signs of radiation toxicity. At 24h
after injection no radioactivity was detected in mice
because of the excretion and complete radioactive decay
of the relatively short-lived isotope 18F (half-life 110 min).
No changes in eating and drinking habits, urine and fecal
excretion, or body weight were seen.
Damage to the tumors by 18F-FDG
Figure 2 shows microscopic images of small and large
tumors from PyMT mice. The small (0.15–0.17cm diame-
ter) tumors from 10-week-old mice treated with 18F-FDG
had numerous apoptotic cells clearly present in the center
of the treated tumors (Fig.2a) that were not detected in
untreated tumors (Fig.2b). Overall, 4±1% of cells in the
treated small tumors were apoptotic, in comparison with
less than 1% in untreated tumors (P<0.05). No apoptosis
or necrosis was detected in the healthy mammary glands
of C3H/B6 mice treated with 3mCi of 18F-FDG (Fig.2c).
18F-FDG treatment also caused much more cell death
through the necrotic pathway in large (more than 1cm)
tumors in 22-week-old mice than occurred in untreated
tumors (Fig.2d,e). In the treated tumors, the areas occu-
pied by necrotic cells were stained brown–yellow
(Fig.2d), as opposed to the sheets of bluish tumor cells in
untreated controls (Fig.2e). Necrotic areas constituted
14% of the tumor volume in 22-week-old mice. Some
apoptotic cells were also visible at the rim of the necrotic
area.
Figure 2f,g displays H&E-stained large tumors from
22-week-old PyMT mice. Tumors that had been treated
with  18F-FDG were bloody when sectioned, which sug-
gests resorption. This observation was confirmed by heavy
infiltration of leukocytes in the H&E-stained section
(Fig.2f). Furthermore, the sections of the tumors treated
with  18F-FDG showed a loss of coherence of the tumor
cells with breaks in the epithelial sheets (Fig.2f) as
opposed to solid sheets of tumor cells found in the
untreated controls (Fig.2g).
18F-FDG-PET in breast cancer patients with metastatic
disease
Table 1 summarizes the SUVs for metastatic tumors,
SUVs for normal liver and TLRs in patients with metastatic
breast cancer imaged with 18F-FDG.  18F-FDG-avid
metastatic breast cancer in five retrospectively studied
patients showed an average TLR of 2.7±0.8. Figure 3
presents a 18F-FDG-PET projection image of a patient
with breast cancer, metastatic to the right lung. A left lung
metastasis was also seen. Normal activity in the heart,
liver, kidneys, bladder, and bowel was observed. It should
be also noted that the primary breast cancer had previ-
ously been resected, and the residual normal non-lactating
breast tissue did not display increased 18F-FDG uptake
Available online http://breast-cancer-research.com/content/5/6/R199over the background. The SUV within a tumor was
uniform, because our patients did not display areas of
necrosis in the tumors. In patients with multiple tumors the
SUVs varied from site to site. In patient 5, the most intense
SUV was 9.9 in the tumor with a diameter of 5cm, and the
least intense SUV was 2.9 in the tumor with a diameter of
1.5cm. In patient 3, the SUV was 5.8 in the tumor with
dimensions 10cm×6cm×4.5cm, and the lowest SUV
was 3.8 in the tumor with a diameter of 2cm.
The activity of 18F-FDG to deliver 200rad to the red marrow
was calculated to be 4.76Ci for a 70kg woman, and the
subsequent tumor doses were calculated to be 220, 1100,
and 2200 rad for SUVs of 1, 5, and 10, respectively. The
activity of 18F-FDG to deliver 300rad to the red marrow was
calculated to be 7.14Ci, and tumor doses would be 330,
1650, and 3300 rad for SUVs of 1, 5, and 10, respectively.
These doses are in the tumoricidal range.
Discussion
We have reported the use of positrons for the treatment of
malignancy. Theoretically, these positrons can kill cancer
cells in the same manner as electrons. However, the cytoci-
dal potential of positrons remains largely unexplored. His-
torically, owing to the early success of the therapy of
thyroid cancer with 131I, which emits electrons, much of the
further development of radiopharmaceuticals for cancer
therapy has concentrated on electron-emitting radioiso-
topes. The only reported use of the cytocidal potential of
positrons was described by Stoll and colleagues [10], who
used a balloon filled with the positron-emitter 68Ga for
coronary artery brachytherapy to prevent restenosis.
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Figure 1
Coronal FDG-PET images of mice acquired 1 h after i.p. injection of 18F-FDG. Slices (2mm thick) with the highest activity in the tumor were
chosen. All mice were lying on their backs with the heads pointing up. Tumors are marked with arrows. Because 18F-FDG is normally excreted in
the urine, bladder activity is visible in all mice. The highest radioactivity uptake shows as red. (a) PyMT mouse with an abdominal mammary tumor.
(b) PyMT mouse with a thoracic mammary tumor. (c) MMTV-neuT mouse with a thoracic mammary tumor. (d) Tumor-free MMTV neuT mouse: no
abnormal uptake is seen.Metabolic trapping of 18F-FDG is an attractive mechanism
for delivering radioactivity to tumors, because neoplastic
cells have an enhanced rate of glucose utilization [11].
This mechanism has been used successfully in 18F-FDG-
PET, which is widely used in nuclear medicine for the
diagnosis of oncological diseases. 18F-FDG has the ability
to remain in cancer cells with low efflux rates. With a phys-
ical half-life of almost 2hours, 18F emits energetic
positrons with high abundance (96%) and a path length in
tissue of about 0.1–0.2cm. These qualities make 18F-FDG
a potential candidate for investigation as an agent for the
treatment of breast and other cancers.
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Figure 2
Apoptosis and necrosis caused by treatment with 18F-FDG in mammary tumors in PyMT mice. Apoptotic and necrotic cells were detected with an
Apoptag Plus apoptosis detection kit. (a) A treated tumor in a 10-week-old mouse has numerous apoptotic cells present (stained brown) in the
center of the tumor. (b) An untreated tumor in a mouse of the same age has an insignificant number of apoptotic cells. (c) Healthy mammary glands
of C3H/B6 mice treated with 3mCi of 18F-FDG: no apoptotic or necrotic cells are present. (d) A treated tumor in a 22-week-old mouse shows
extensive necrotic areas (stained brown–yellow); some apoptotic cells are also seen at the rim of the necrotic area. (e) An untreated tumor in a
22-week-old mouse. (f) An H&E-stained treated tumor in a 22-week-old mouse: heavy infiltration by leukocytes and a loss of coherence of the
tumor cells with breaks in the epithelial sheets are observed. (g) An untreated tumor in a mouse of the same age shows solid sheets of tumor cells.
Original magnifications: (a–c) ×400; (d–g) ×200.
Table 1
Standardized uptake values (SUVs) for metastatic tumors and normal liver; and tumor to liver ratios (TLRs) in patients with
metastatic breast cancer imaged with 3.5 mCi of 18F-FDG
SUV
Patient Diagnosis Metastasis Normal liver TLR
1 Metastasis to sub-carinal lymph node 5.3 2.8 1.89
2 Metastasis to the left axilla 7.4 2.3 3.36
3 Liver metastasis 5.8 2.6 2.23
4 Metastasis to the right axilla 5.3 2.1 2.52
5 Right lung metastasis 9.9 2.7 3.67
SUVs were calculated for all regions of interest by the formula SUV=(activity in tissue [mCi/g] divided by (injected activity [mCi]/body weight [g]).
TLRs were calculated by the formula TLR=SUV of tumor divided by SUV of liver.Our imaging experiments in two different mouse mammary
cancer models (the PyMT model of murine mammary
cancer and the MMTV NeuT model, which carries the
erbB-2 human breast cancer oncogenes) showed that it is
possible to use these models for the investigation in vivo
of the tumoricidal properties of positrons, because tumor
uptake was demonstrated. We observed apoptosis and
necrosis in tumors treated with 18F-FDG; particulate ioniz-
ing radiation is known to cause cell death through both
the apoptotic [12] and necrotic pathways [13,14]. In small
tumors (0.15–0.17cm in diameter) in PyMT mice treated
with 18F-FDG, the prevalent mode of cell death was apop-
tosis, whereas in large tumors (more than 1cm in diame-
ter) the radiation induced widespread necrosis. A possible
explanation for this difference is that as the tumor diameter
increased and there was an exponential increase of the
absorbed radiation dose to the tumor, the high doses of
radiation to the cell surface led to the focal stimulation of
tumor necrosis factor-α expression [13] and a high influx
of calcium [14], which induced necrosis instead of apop-
tosis. 18F-FDG at the 2–4mCi doses that were used for
the therapy of tumor-bearing animals contained
0.001–0.002mg of unlabelled FDG, which should not
cause any pharmacological effect because the level of
glucose in the blood at fasting is 0.7mg/ml (70mg/dl).
A retrospective study of five patients with metastatic
breast cancer imaged with 18F-FDG provided high SUVs
in the tumors (2.7±0.8). In patients with multiple tumors
the SUVs varied from site to site. The tumors with greater
uptake of the non-metabolite are affected more than the
tumors with less uptake during positron therapy. The SUV
of small tumors might suffer from volume averaging in
measurement, and these tumors might actually receive a
higher dose to the tumor than was measured. The dose-
limiting organ for 18F-FDG administration is the red
marrow. Other normal tissues show high 18F-FDG uptake,
but they are relatively radioresistant. There are methods to
reduce uptake by normal tissue. Uptake by cardiac and
skeletal muscle is routinely reduced by fasting, and uptake
by skeletal muscle can be further reduced with benzodi-
azepine therapy [15]. Uptake by brain is impossible to
avoid. With an administered dose of 7.14Ci of 18F-FDG,
the dose to the brain is 570rad. In external beam brain
radiation therapy, 5040rad is given in 28 fractions of
180rad each, accompanied by corticosteroid therapy to
decrease brain inflammation and edema [16]. The
18F-FDG therapy dose can be also be fractionated and
corticosteroids can be administered to prevent toxicity to
the brain. The dose to the bladder and kidneys can be
reduced with a Foley catheter and diuretic administration
[17]. These data suggest that 18F-FDG therapy can be
used safely in 18F-FDG-avid malignancies.
With regard to long-term toxicity from positron therapy, it
has been shown that after large cumulative doses of 131I
for metastatic thyroid cancer, the risk of secondary
leukemia is 0.4 deaths per 104 patient-year-grays [18].
We would expect patients with metastatic breast cancer
treated with high doses of FDG to have a similar risk for
latent leukemia. Patients who require whole-brain radiation
therapy generally do not live long enough to attain a sec-
ondary malignancy, and there are no data on this.
One other possible advantage of using 18F-FDG as a ther-
apeutic agent in breast cancer is that up to 29% of
glucose utilization in the tumor is due to uptake in non-
neoplastic cells, mostly macrophages [19]. In a mouse
model it has been shown that macrophages contribute to
tumor progression and metastasis [20]. Thus, treatment
with 18F-FDG of metastatic breast cancer with poor prog-
nosis could be particularly suitable because the
macrophages are targeted in addition to the tumor cells.
We can envisage the application of other positron-emit-
ters that have longer half-lives and emit higher-energy
positrons than those emitted by 18F for positron tumor
therapy. For example, 76Br-labeled bromo-D-glucose [21]
could potentially deliver a higher radiation dose to the
tumor because 76Br has a longer half-life (16.2 hours) than
18F and emits positrons with an energy of 3.44MeV. Other
compounds of interest for positron tumor therapy might
include  124I-labeled iododeoxyuridine (half-life 4.2 days,
energy 2.13MeV), which incorporates into the DNA of
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Figure 3
18F-FDG-PET projection image of a patient with breast cancer
metastatic to the right lung. A metastasis to the left lung is also visible.
Normal activity is observed in the heart, liver, kidneys, bladder, and
bowel. The primary breast cancer had previously been resected, and
the residual normal non-lactating breast tissue did not display
increased 18F-FDG uptake over the background.cancer cells, and 64Cu-pyruvaldehyde bis(N-methylth-
iosemicarbazone) (half-life 12.7hours, energy 0.657MeV)
for the treatment of hypoxic tumors.
Conclusion
We have shown, to our knowledge for the first time, that
positrons delivered by 18F-FDG to mammary tumors in
mice cause apoptosis and necrosis of breast cancer cells.
The dosimetry of 18F-FDG for tumors and normal organs in
breast cancer patients suggests that 18F-FDG is a candi-
date for the radiomolecular therapy of refractory breast
cancer and other cancers.
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